Compare CYD & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | IMNM |
|---|---|---|
| Founded | 1951 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 1994 | 2020 |
| Metric | CYD | IMNM |
|---|---|---|
| Price | $34.75 | $19.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $26.89 |
| AVG Volume (30 Days) | 164.2K | ★ 1.3M |
| Earning Date | 08-08-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 40.10 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $3,159,401,156.00 | $9,679,000.00 |
| Revenue This Year | $41.12 | N/A |
| Revenue Next Year | $6.93 | N/A |
| P/E Ratio | $20.90 | ★ N/A |
| Revenue Growth | ★ 17.99 | N/A |
| 52 Week Low | $8.61 | $5.15 |
| 52 Week High | $42.60 | $20.46 |
| Indicator | CYD | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 64.30 |
| Support Level | $34.75 | $16.81 |
| Resistance Level | $36.30 | $18.96 |
| Average True Range (ATR) | 1.56 | 1.22 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 47.70 | 85.21 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.